NASDAQ
16.01.26 | 22:00
1,170 US-Dollar
-3,31 % -0,040
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 | 90 | GlobeNewswire (Europe) | - First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim... ► Artikel lesen | |
| 08.12.25 | ALXO Presents Phase 2 Data Of Evorpacept In Frontline Indolent Non-Hodgkin Lymphoma At The ASH | 1 | RTTNews | ||
| 07.12.25 | ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting | 174 | GlobeNewswire (Europe) | - Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an... ► Artikel lesen | |
| 13.11.25 | Jefferies initiates coverage on ALX Oncology stock with Buy rating | 4 | Investing.com | ||
| 07.11.25 | ALX Oncology anticipates $2B-$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies | 6 | Seeking Alpha | ||
| 07.11.25 | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Earnings Call Transkript: ALX Oncology zeigt vielversprechende Fortschritte bei Medikamentenentwicklung in Q3 2025 | 2 | Investing.com Deutsch | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 07.11.25 | ALX Oncology GAAP EPS of -$0.41 misses by $0.04 | 3 | Seeking Alpha | ||
| 07.11.25 | ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 209 | GlobeNewswire (Europe) | ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast... ► Artikel lesen | |
| 07.11.25 | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 06.11.25 | Examining the Future: ALX Oncology Holdings' Earnings Outlook | 2 | Benzinga.com | ||
| 23.10.25 | Alx Oncology stock jumps after presenting preclinical ADC data at conference | 3 | Investing.com | ||
| 23.10.25 | Präklinische ADC-Daten beflügeln Aktie von Alx Oncology | 1 | Investing.com Deutsch | ||
| 23.10.25 | ALX Oncology stellt präklinische Daten für neuartigen EGFR-Krebswirkstoff vor | 7 | Investing.com Deutsch | ||
| 23.10.25 | ALX Oncology presents preclinical data for novel EGFR cancer drug | 1 | Investing.com | ||
| 03.10.25 | ALX Oncology to present CD47 biomarker data for evorpacept at SITC | 1 | Investing.com | ||
| 03.10.25 | ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 12.09.25 | ALX Oncology appoints board member Klencke as interim CMO | 2 | Investing.com | ||
| 12.09.25 | ALX Oncology CMO Alan Sandler Resigns; Appoints Board Member Barbara Klencke As Interim CMO | 1 | RTTNews | ||
| 12.09.25 | ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer | 299 | GlobeNewswire (Europe) | Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,070 | -4,05 % | Aixtron, Energiekontor, Evotec, HelloFresh, Hugo Boss, Renk, TUI - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| MODERNA | 35,465 | -1,58 % | Biontech-Konkurrent Moderna im Aufwind: Ist das die Wende? | Die Aktien des Biontech-Rivalen Moderna setzen ihren Aufwärtstrend fort. Am Vormittag steigen sie um drei Prozent, nachdem sie gestern im US Handel zeitweise um 17 Prozent nach oben geschnellt waren.... ► Artikel lesen | |
| NOVAVAX | 6,645 | -3,60 % | NOVAVAX INC unter Beobachtung - Fokus auf Substanz | ||
| CRISPR THERAPEUTICS | 45,200 | -2,16 % | CRISPR Therapeutics-Aktie: Wird die Geduld belohnt? | Die Aktie von CRISPR Therapeutics sorgt seit Jahren für starke Volatilität in beide Richtungen und stellt selbst erfahrene Anleger vor Geduldsproben. Zwischen Hoffnungen auf medizinische Durchbrüche... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,340 | +1,52 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,200 | -5,25 % | Cathie Wood's ARK adds to Intellia stock holdings on January 15 | ||
| DEFENCE THERAPEUTICS | 0,393 | -2,72 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| EDITAS MEDICINE | 1,779 | +1,40 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,990 | -2,29 % | BioMarin Pharmaceutical Inc.: BioMarin Appoints Arpit Davé Chief Digital and Information Officer | Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,695 | -2,83 % | Johnson Fistel, PLLP: Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty | San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,760 | -7,81 % | PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases | MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration... ► Artikel lesen | |
| EXELIXIS | 36,820 | -2,90 % | Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO | ||
| HALOZYME THERAPEUTICS | 60,98 | -0,68 % | Halozyme Therapeutics, Inc.: Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE | Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab
SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 112,10 | -1,75 % | Major Decision: Darin Lippoldt Exercises Options, Realizing $320K At Neurocrine Biosciences | ||
| EXACT SCIENCES | 88,65 | +0,36 % | Laufende Fusionskontrollverfahren: Abbott Laboratories, Abbott Park (North Chicago) Illinois/USA; Erwerb aller Anteile an der und alleiniger Kontrolle über die Exact Sciences Corporation, Madison/Wisconsin/USA | Datum der Anmeldung:08.01.2026Aktenzeichen:B3-24/26Unternehmen:Abbott Laboratories, Abbott Park (North Chicago) Illinois/USA; Erwerb aller Anteile an der und alleiniger Kontrolle über die Exact Sciences... ► Artikel lesen |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,31 % bei einem Aktienkurs von 1,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.